Royalty Pharma (NASDAQ:RPRX) PT Raised to $50.00 : compareme

Royalty Pharma (NASDAQ:RPRX – Get Rating) had its target price lifted by investment analysts at Morgan Stanley from $48.00 to $50.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 36.87% from […]

Related Keywords

United States , Marshall Urist , Roryb Riggs , Morgan Stanley , Voya Investment Management , Victory Capital Management Inc , Securities Exchange Commission , Macquarie Group Ltd , United Capital Financial Advisers , Royalty Pharma , Get Rating , Director Rory , Exchange Commission , Ivy Capital Management , Capital Management , Investment Management , Capital Financial Advisers , Royalty Pharma Daily , Nasdaq Rprx , Rprx , Finance , 76028h20 , Boost Price Target ,